CD19-redirected Autologous Cells (CAR-CD19 T Cells)

Clinical trial NCT02933775 · UNKNOWN

Trial details

NCT number: NCT02933775
Sponsor: RenJi Hospital
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

CD19 Positive Malignant B-cell Leukemia and Lymphoma

Start date: 2016-10-01
Primary completion: 2018-04-01
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.